Among AML patients with CEBPAdm, Grossmann et al. from Germany reported that TET2 was found to be the most frequently mutated gene (34.0%), followed by GATA2 (21.0%), and WT1 (13.7%) genes [9]. This evidence concerns the gene WT1 and acute myeloid leukemia.